Now Recruiting: ION283 Safety Study
The application packet for the ION283 safety study is now available!
You can view the application as a PDF or download a Word document.
Please read the email below from Dr. Minassian:
“Dear Lafora disease patients and families,
We are now ready to receive referrals for consideration for inclusion into the clinical trial: Safety and Efficacy of Intrathecally Administered ION283 in Patients with Lafora Disease
This email relates to the prescreening phase. Below are the requirements for the prescreening. If a patient passes the prescreening, they will be placed on a list of prospective patients to participate in the trial. Each patient invited to participate will still need to meet broader inclusion-exclusion criteria at the time of screening in Dallas. These final inclusion-exclusion criteria are listed in the above website.
Only referrals from neurologists will be accepted, except where it is impossible for the patient to have a neurologist (we are thinking of the patient in Gaza), in which case another doctor or local medic can make the referral.
Attached is a document that contains a prescreening table and the Lafora Disease Performance Scale, both of which should be completed by the referring neurologist. All parts of the document must be completed. All documents and video mentioned in the prescreening table must be provided at the time of referral precisely as described.
Referrals must be sent by the neurologist from his or her email address to LDrecruiting@utsouthwestern.
The list of prospective participants will be generated on a first-come first-served basis, where first-come means that all the above requirements are included in the referral. Any referral that has any component missing will not be accepted and will be returned.
The study will only include 10 participants. Therefore, the first 10 on the first-come list will be invited to Dallas for formal screening toward potentially entering the study. If any patient among the first 10 fails to meet inclusion-exclusion criteria at the time of final screening in Dallas, then this will open a slot for a subsequent patient on the list.
The upper age limit is 18. We understand this to mean any patient before their 19th birthday at the time of final screening in Dallas. In case among the first 10 patients passing prescreening there is a patient whose turn in the list means they will age out of their 19th birthday at the time of the final screen in Dallas, such a patient may be moved up the list as long as this does not affect the age-criterion admissibility of the remaining patients.
Thank you for considering participation in this clinical trial.
Berge A. Minassian, MD
Principal Investigator
University of Texas Southwestern”
Our deepest gratitude goes to Dr. Minassian, Dr. Joshi, Dr. Verma, Dr. Messahel, and the entire team at UTSW for making this possible. We are also thankful for Ionis’ drug donation and our community’s collective fundraising efforts. We can’t stop now!
Please help us share this information, and good luck to everyone applying.
Chelsea’s Hope, Post Office Box 348626, Sacramento, CA 95834
